Looking at top Wall Street opinions, TransEnterix, Inc. (NYSE: TRXC) has recently made its way into the research list of RBC Capital Mkts – signaling that their analyst’s rating adjustment is noteworthy. This stock was downgraded to a rating of Sector Perform in the eyes of RBC Capital Mkts, whereas its previous rating was Outperform in the eyes of RBC Capital Mkts, as reported on Thursday, August 8th, 2019. Another heavy-hitting research note was published by Piper Jaffray on Wednesday May 22nd, 2019, with this firm Initiated TRXC to an updated rating of Neutral. In the past six months and three months of trading, shares of TransEnterix, Inc. (TRXC) have moved by -63.41% and -21.71%, respectively.
Brokerage Updates Related to TransEnterix, Inc. (TRXC) Stock
Not a Single analyst have given underperform rating or sell rating, and 3 have given a rating of Buy or better. Based on the 6 stock market experts following this company, the average 12-month price target is $1.38. Moreover, individual price targets range between $1.00-$1.50. With its recent move to $1.50, we can see that these firms project this stock will loss by -77.25% in one year.
Updates from TransEnterix, Inc. (TRXC) SEC Form 4
This particular company’s shares have garnered a lot of attention in recent days, as insiders are unloading their holdings while having generated a 2.60% rise since the beginning of the calendar year. A EVP and CFO at TransEnterix, Inc. (TRXC) sold off some of its shares in a transaction that was finalized on Feb 22. Similarly, SLATTERY JOSEPH P sold 17,650 shares of the organization’s stock at $3.25 apiece and racked up $57,363 in earnings from the sale. Now, SLATTERY JOSEPH P holds 44,929 shares of the company following the exchange. A EVP and CFO of the organization named SLATTERY JOSEPH P, was engaged in a transaction that occurred on Oct 02 that managed to be worth $49,045 from the sale of 8,500 common shares at a price of $5.77 per individual share.
TransEnterix, Inc. (NYSE:TRXC) Results in the Pipeline
The next scheduled release of financial results for TransEnterix, Inc. will be for the Jun-19 quarter. In the same vein, they expect sales for the quarter to amount to $5.03 million.
Now let’s turn to earnings surprise history: in the most recent quarter, the company reported about $3.64 million. On average, the analyst projection was calling for $2.18 million. In the preceding quarter, this company’s revenue reached $7.52 million.
Assertio Therapeutics, Inc. (NASDAQ:ASRT) experienced a drop of -1.23% from the closing price in the previous trading day. That drove the price to $1.60 per share, as observed on January 1st, 1970, at a time when the total trading volume reached 1,940,829 shares of stock – compared to the typical average of 1.06M shares per day (as recorded over the past three months). The consensus estimate for these shares has been shifted to $4.88.
Pricing Indications for Assertio Therapeutics, Inc. (ASRT)
This organization has had a price-to-earnings ratio of in the last year. Meanwhile, it gained 2.94 from its observable 50-day simple moving average. Right at this moment, the per-share value is -60.34% lower than the mean per-share price over the last 200 days in the market.
Assertio Therapeutics, Inc. (NASDAQ:ASRT) In-Depth Brokerage Insights
We can see that a number of brokerage firms are putting their focus onto this stock. Out of this group, 0 have a sell rating, 0 have a Buy rating, 1 have an outperform rating, while 2 provided a Hold rating for these shares – thanks to data from Thomson Reuters I/B/E/S. Additionally, 0 have recommended that these shares are an Underperforming investment. The current consensus recommendation is at 2.70, based on information from Thomson Reuters.
ASRT Stock Value Potential
In trading activity as of late, this stock’s value was 4.02 up from its 200 day moving average, while also -46.05% down when compared against its 50-day simple moving average. Over the course of the past year of trading, the share price stuck in the range of $3.00-$9.50. The market value for the entire organization reached 103.10M. In the last trading session, the price ended the day at $1.62. The institutional holdings related to this organization account for 1.20%, and the Beta factor is now 2.02. This company’s RSI (Relative Strength Index) managed to hit 25.46.
Assertio Therapeutics, Inc. (NASDAQ:ASRT) Analyst Points of Focus
Assertio Therapeutics, Inc. (ASRT) has found itself inside of Mizuho’s research list, so their analyst rating adjustment is worth taking note of.